CurrentUnitedHealthcarePolicy CSNCT0358.02

Sacral Nerve Stimulation for Urinary and Fecal Indications (for North Carolina Only)

Clinical evidence review and guideline summary regarding sacral nerve stimulation (SNS/SNM) for indications including fecal incontinence, low anterior resection syndrome (LARS), chronic pelvic pain, constipation, urinary voiding dysfunction, and neurologic-origin bladder/bowel dysfunction; includes guideline recommendations, contraindications, trial/test-phase success criteria, and evidence strength summaries. (This is Part 2 of 3; content limited to pages provided.)

Policy Summary

PayerUnitedHealthcare

PolicySacral Nerve Stimulation for Urinary and Fecal Indications (for North Carolina Only)

Policy CodePolicy N/A

Change TypeRevised/Added clinical, documentation, and coding guidance

Effective DateDec 1, 2025

Next Review Date

Key ActionDocument >=50% improvement in target urinary or bowel parameters during PNE or Stage 1 test period to justify permanent implantation.

SourceLink

POLICY UPDATE CHANGES

Replaced references to 'Sacral Nerve Stimulation' with 'Sacral Nerve Stimulation (neurostimulation)'; updated Medical Records Documentation language to require documentation supporting medical necessity.

Added notation that CPT/HCPCS codes 0784T, 0785T, 0786T, 0787T, L8679, L8680, L8682, L8685, L8686, L8687, and L8688 are not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by NC Medicaid.

Added definition of 'Sacral Nerve Stimulation (SNS) [Also Known as Sacral Neuromodulation (SNM) or Urologic Nerve Stimulation]'.

Updated Clinical Evidence, FDA, and References sections to reflect current information, including recent FDA PMA approvals and literature updates.

Archived previous policy version CSNCT0358.01.

35.2%Aggregate revision rate (SNM for FI)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Part 2 of 3 — Policy metadata: Effective Date: 2025-12-01. Scope: clinical evidence review and guideline synthesis for Sacral Nerve Stimulation (SNS/SNM) for urinary and fecal indications, including test-phase criteria and documentation requirements. Coverage stance: mixed — some indications have robust supportive evidence and guideline endorsement, while others lack sufficient or consistent evidence.

Indications with stronger supporting evidence and guideline endorsement include fecal incontinence (FI) and selected urinary indications such as overactive bladder (OAB)/urgency urinary incontinence (UUI) and non-obstructive urinary retention (NOUR). Multiple professional societies (ICS, EAU, AUA/SUFU, NICE, ASCRS, ACG) and systematic reviews/meta-analyses report symptom and quality-of-life improvements and recommend offering SNM for refractory FI and for refractory OAB/NOUR in appropriately selected adults; long-term cohort and pooled data support sustained benefit for many patients.

Indications with weaker or insufficient evidence include constipation (slow-transit constipation), chronic pelvic pain (CPP), and voiding or bowel dysfunction secondary to neurologic disease. Randomized trials and systematic reviews show conflicting or limited results for constipation and CPP, and guideline statements classify these uses as investigational, unsupported, or requiring more high-quality data. FDA device approvals and recent PMAs (e.g., Neuspera P240031; existing PMAs for InterStim and Axonics) provide device-specific regulatory context but do not by themselves establish broad coverage.

High-level operational notes: permanent implantation coverage is tied to achieving test-phase success (typical threshold >= 50% improvement during PNE or Stage 1), documentation of medical necessity in the record, and adherence to test durations and patient-selection considerations described in the policy. CPT/HCPCS coding and state-specific coverage limitations are noted separately.

Numeric thresholds & common test durations (policy)

Test-phase response threshold>= 50% improvement in one or more troublesome urinary or bowel parameters

PNE duration (bladder)typically 7 days

PNE duration (bowel)typically 10-21 days

Stage 1 durationtypically 2-3 weeks

Test success threshold>= 50% improvement during PNE or Stage 1

Medical-Necessity / Implantation Criteria

General Test-Phase Success / Implantation Criteria

Coverage for permanent implantation is supported when test-phase success criteria are met:

ALL of the following

Individual meets indication-specific screening trial criteria (urinary or fecal) as defined elsewhere in this policy.
Documented improvement in reported symptoms in response to a screening trial of Sacral Nerve Stimulation.>= 50%
Ability to operate device
- Individual is capable of operating the sacral nerve stimulating device independently.

Population-Specific Evidence & Coverage-Relevant Conclusions

Population-Specific Evidence Statements (coverage-relevant conclusions)

Evidence-supported / insufficient areas summarized:

Fecal incontinence: multiple systematic reviews and long-term studies show improvement in continence and QoL; success rates variable; complications/revision/explant rates substantial (revision ~35.2%, explant ~19.7%).

Evidence limited by lack of comparative trials and heterogeneity

LARS (post-low anterior resection FI): SNM shows symptom and QoL improvement; PNE test success ~76.3% and overall permanent implant success ~83.3% (pooled).

Based on systematic trials and meta-analyses

Chronic pelvic pain (CPP): evidence insufficient overall; some systematic reviews/case series suggest pain reduction and QoL improvement but lack RCTs and have bias; use considered investigational/limited.

Mixed results; further high-quality RCTs needed

Coding

No procedure or billing codes present in this partmixed

No codes listed

Codes noted as not on State of North Carolina Medicaid Fee Schedule (may not be covered by NC Medicaid)CPT|HCPCSNot Covered

0784T
0785T
0786T
0787T
L8679
L8680
L8682
L8685
L8686
L8687

1–10 of 11

1/2

Provider Actions & Operational Requirements

Documentation Required

Document test-phase improvement

Document that the individual achieved ≥50% improvement in one or more targeted urinary or bowel parameters during the PNE or Stage 1 test period when justifying permanent IPG implantation.

Prior Authorization

Use of test-phase to determine implantation

Perform and document a trial stimulation (PNE or Stage 1) with typical durations (PNE: ~7 days for bladder; PNE: ~10–21 days for bowel; Stage 1: ~2–3 weeks). Record test stimulation outcomes prior to permanent IPG implantation.

Documentation Required

Preoperative counseling

Discuss and document preoperative counseling that includes the need for life-long follow-up, future battery replacement, risks (implant site pain, infection, paresthesia, leg pain), possibility of reprogramming, and likelihood of device revision or explantation; set realistic expectations for success and complication/revision rates.

Background, Evidence & Guidelines

Background synthesis: This policy integrates data from clinical trials, systematic reviews, meta-analyses, and professional guidelines addressing SNS/SNM for urinary and bowel dysfunction. Evidence quality and quantity vary by indication: stronger evidence and guideline support exist for FI and certain urinary indications (OAB/UUI, NOUR); evidence is mixed or insufficient for constipation, CPP, and many neurologic-origin dysfunctions.

Clinical trial and systematic-review findings: multiple systematic reviews and long-term studies report improvements in continence and quality of life with SNM for FI, though revision and explant rates are substantial. Network and meta-analyses and randomized trials support SNM as an effective third-line option for refractory OAB/UUI with responder rates often around the policy's test threshold. For constipation, randomized and crossover trials have produced conflicting or negative findings and systematic reviews conclude evidence is insufficient. CPP literature consists largely of case series and few RCTs with heterogeneous results, yielding an overall conclusion of insufficient high-quality evidence.

Guideline recommendations: Professional societies provide condition-specific guidance: ICS, EAU, AUA/SUFU, NICE, ASCRS, ACG and others recognize SNM as an option for refractory OAB/UUI and for FI (often as second-line or surgical option after conservative measures), recommend trial stimulation and long-term follow-up, and characterize constipation and CPP uses as not routinely supported or requiring more evidence. Guidelines also outline contraindications, test-phase practices, and counseling requirements.

Regulatory/devices: FDA premarket approvals and device-specific actions are noted for context (e.g., InterStim and Axonics PMAs; Neuspera PMA P240031 announcement). Device approvals inform available technologies but do not by themselves determine coverage.

Evidence variability and implications: Because evidence strength is indication-dependent, the policy takes a mixed stance—supporting coverage for permanent implantation when documented test-phase success and selection criteria are met for indications with supportive evidence, while categorizing constipation and CPP as unproven/not medically necessary absent stronger data. The policy also emphasizes the need for medical-record documentation of history, exam, diagnostic test results, and trial outcomes to support medical necessity.

Definitions

Definitions (policy)

PNEPercutaneous Nerve Evaluation — temporary test stimulation period prior to permanent SNM implantation

Stage 1 testSurgical test lead implantation with a longer trial period (typically 2-3 weeks) prior to full system implantation

IPGImplantable Pulse Generator — permanent SNM device component

NOURNon-obstructive urinary retention

SNM / SNSSacral Neuromodulation / Sacral Nerve Stimulation (also called Urologic Nerve Stimulation)

Revision History

12/01/2025material_changeLatest

Replaced references to 'Sacral Nerve Stimulation' with 'Sacral Nerve Stimulation (neurostimulation)' and updated Medical Records Documentation language to require documentation supporting medical necessity (relevant medical history, physical exam, and results of pertinent diagnostic tests; legible, maintained in record, and made available upon request).

12/01/2025material_changeLatest

Added operational note that CPT/HCPCS codes 0784T, 0785T, 0786T, 0787T, L8679, L8680, L8682, L8685, L8686, L8687, and L8688 are not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by NC Medicaid; verify state-specific coverage and prior authorization requirements.

Policy Summary

PayerUnitedHealthcare

PolicySacral Nerve Stimulation for Urinary and Fecal Indications (for North Carolina Only)

Policy CodePolicy N/A

Change TypeRevised/Added clinical, documentation, and coding guidance

Effective DateDec 1, 2025

Next Review Date

Key ActionDocument >=50% improvement in target urinary or bowel parameters during PNE or Stage 1 test period to justify permanent implantation.

SourceLink

On This Page

Preoperative counseling / informed consent: The treating clinician must document that the individual received and understood counseling on the risks, benefits, alternatives (including continued conservative therapy and other procedural options), expected outcomes, device lifecycle (including potential need for revisions/replacements), and activity or device-use restrictions. Informed consent must include discussion of trial-stage purpose and success criteria, possibility of no benefit after permanent implantation, risks of infection, lead migration or malfunction, need for future MRI limitations or conditional MRI planning, and implications for future surgeries or pregnancy. Documentation should confirm the individual (or caregiver) understands device management, charging/replacement requirements (if applicable), and follow-up schedule.

Absolute Contraindications

ALL of the following

Insufficient or absent improvement during the screening trial (does not meet the policy threshold of >= 50% improvement).
Individual lacks capacity to participate in device management and no consistent, capable caregiver is available to operate the device.
Known pregnancy at the time of consideration for implantation.

Note: Absolute contraindications should be clearly documented in the medical record; absence of these is required before proceeding to permanent implantation.

Relative Contraindications / Cautions

ANY of the following

Severe or progressive neurologic disease where progression may alter expected benefit (e.g., rapidly progressive neurodegenerative disorders).
Complete spinal cord injury where intact sacral nerve pathways are absent, limiting expected benefit from stimulation.
Anticipated need for frequent or emergent full‑body MRI incompatible with implanted device variants (unless MRI conditional device and planned MRI protocols are acceptable).
Marked abnormal sacral or pelvic anatomy (e.g., prior surgery, congenital malformation) that would preclude appropriate electrode placement or stable stimulation responses.

Clinical caution: These are relative contraindications — individual patient circumstances and specialist assessment should guide decision-making; documentation of rationale is required if proceeding despite cautions.

Screening during test stimulation (PNE or Stage 1)

Screening during test stimulation (PNE or Stage 1):

ALL of the following

Documented improvement in target symptoms of >= 50% during the test stimulation period (measured by symptom diary, validated scores, or clinician assessment).>= 50%
Typical test durations: percutaneous nerve evaluation (PNE) trial often lasts several days up to 1 week; staged (tined lead) trials commonly last 7–14 days or per device-specific guidance. Clinical judgment may extend or shorten trial duration with documentation.
Clinician considerations: document sensory and/or motor responses during test stimulation (e.g., appropriate pudendal/sacral sensory perception, toe plantarflexion) and correlate with symptom improvement; record stimulation parameters used and any adverse effects noted.

Operational note: Clear documentation of baseline symptom severity and method of measuring % improvement is required (e.g., voiding diaries, incontinence episode counts, bowel movement logs, validated questionnaires).

Successful outcome definition and follow-up

Successful outcome definition and follow-up:

ALL of the following

Successful outcome is defined as sustained symptom improvement of >= 50% compared with baseline after permanent implantation, with demonstrable benefit documented on follow-up assessments.
Follow-up: Patients (or caregivers) should have a documented follow-up plan including device programming/optimization visits, assessment of symptom response, management of adverse events, and long-term device surveillance. Initial post-implant follow-up is typically within weeks of implantation with ongoing periodic assessments.
Safety notes for neurogenic patients: In individuals with neurologic conditions, special attention should be given to progression of underlying disease, changes in sensation that may mask adverse events (e.g., infection), and coordination with the patient’s neurologist. Documentation should justify expected durable benefit in neurogenic etiologies if implantation is considered.

Operational note: Maintain documentation of informed consent, trial and implant outcome measures, device model and serial numbers, programming settings, and any revisions or complications in the medical record.

Study/Source	Key finding / relevance
Eggers et al. (2025) systematic review	36 studies, 3,770 subjects; long‑term FI improvement reported; aggregate revision rate 35.2% and explant rate 19.7%; high risk of bias
Ram et al. (2020) meta‑analysis — LARS	PNE test success 87/114 (76.3%); pooled permanent implant success ~83.3% (95% CI 71.33–95.26%) — supports SNM for LARS
Zerbib RCT (2017) — refractory constipation	Randomized crossover RCT (n=36) showed no significant difference active vs sham; 11 sustained responders at 1 year — does not support routine SNM for constipation
Heemskerk multicenter RCT (2024) — slow‑transit constipation	At 6 months success 53.7% SNM vs 3.8% PCT (p=0.003); improved QoL but limited long‑term data — promising but insufficient evidence
Test success threshold evidence	Policy/Guideline threshold: ≥50% improvement during PNE or Stage‑1 test required to offer permanent implantation (Level III evidence; Grade C)
Preoperative counseling evidence level	Guidance: counsel on lifelong follow‑up, battery replacement, risks (implant‑site pain, infection, paresthesia, leg pain), reprogramming/revision; Level IV evidence; Grade C
NICE recommendation	NICE (2019/2020): supports SNM for refractory OAB and as option for NOUR with specialist assessment; recommend discussing test stimulation, success probability, long‑term commitment and revision risk
Recent FDA PMA (Neuspera)	Neuspera PMA P240031 announced June 18, 2025 (informational); contextual FDA approvals for InterStim and Axonics also noted